<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04204122</url>
  </required_header>
  <id_info>
    <org_study_id>202003066</org_study_id>
    <nct_id>NCT04204122</nct_id>
  </id_info>
  <brief_title>Vigamox Treatment for Ocular Graft-Versus-Host Disease</brief_title>
  <official_title>Evaluation of Topical Vigamox in the Initial Management of Ocular Graft-Versus-Host Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study the investigators seek to prospectively measure the response of ocular
      graft-versus-host disease (GVHD) patients to treatment with topical Vigamox. The
      investigators will accomplish this by enrolling patients with bilateral ocular GVHD and
      treating one eye with topical Vigamox and the other eye with a placebo eye drop. By assessing
      the response to treatment with Vigamox, the investigators hope to identify a role for topical
      antibiotic treatment in ocular GVHD.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 15, 2020</start_date>
  <completion_date type="Anticipated">July 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The eyes of each enrolled participant will be randomized such that one eye is treated with Vigamox and the other eye is treated with a placebo eye drop.</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Ocular comfort</measure>
    <time_frame>First clinic visit through second clinic visit (estimated to be 9-14 days)</time_frame>
    <description>Ocular comfort will be rated by the participant for each eye on a 0-10 Visual Analog Scale
0=no discomfort and 10=worst discomfort</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Ocular Surface Disease Index (OSDI) score</measure>
    <time_frame>First clinic visit through second clinic visit (estimated to be 9-14 days)</time_frame>
    <description>12 questions with answers ranging from 0=none of the time to 4=all of the time
The OSDIÂ©is assessed on a scale of 0 to 100, with higher scores representing greater disability. The index demonstrates sensitivity and specificity in distinguishing between normal subjects and patients with dry eye disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Visual acuity</measure>
    <time_frame>First clinic visit through second clinic visit (estimated to be 9-14 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Degree of Conjunctival injection</measure>
    <time_frame>First clinic visit through second clinic visit (estimated to be 9-14 days)</time_frame>
    <description>-The degree of conjunctival injection will be graded based on the Validated Bulbar Redness scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Corneal/conjunctival punctate epithelial erosions</measure>
    <time_frame>First clinic visit through second clinic visit (estimated to be 9-14 days)</time_frame>
    <description>The clinical exam will be conducted using the National Eye Institute Fluorescein Staining Scale to grade the degree of corneal and conjunctival stain with a cobalt blue slit lamp filter
This test divides the cornea into 5 sections. Staining is graded on a scale of 0-3, with 0 indicating absence of staining and 3 indicating severe staining.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Culture results</measure>
    <time_frame>First clinic visit through second clinic visit (estimated to be 9-14 days)</time_frame>
    <description>-Conjunctival bacterial cultures will be obtained via swab before and after treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Ocular Graft-versus-host Disease</condition>
  <arm_group>
    <arm_group_label>Arm 1: Eye treated with Vigamox</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>-The participant will be instructed to use one drop from each bottle four times per day for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: Eye treated with placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>-The participant will be instructed to use one drop from each bottle four times per day for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vigamox</intervention_name>
    <description>-FDA approved medication</description>
    <arm_group_label>Arm 1: Eye treated with Vigamox</arm_group_label>
    <other_name>Moxifloxacin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>-The placebo is artificial tear drops</description>
    <arm_group_label>Arm 2: Eye treated with placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -Participants will be adults with a history of allogeneic hematopoietic stem cell
        transplantation, signs of either acute or chronic GVHD per the hematologist, signs and
        symptoms consistent with ocular GVHD + within 4 months of developing symptoms of ocular
        GVHD

        Exclusion Criteria:

          -  Treated with antibiotic eye drops in the month prior to enrollment

          -  History of fluoroquinolone allergy

          -  Asymmetric ocular disease

          -  Pregnant

          -  Nursing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Todd Margolis, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Todd Margolis, M.D., Ph.D.</last_name>
    <phone>314-362-3724</phone>
    <email>margolist@wustl.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christine Martinez, M.D.</last_name>
    <phone>248-535-5420</phone>
    <email>christine.martinez@wustl.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Todd Margolis, M.D., Ph.D.</last_name>
      <phone>314-362-3724</phone>
      <email>margolist@wustl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Christine Martinez, M.D.</last_name>
      <phone>248-535-5420</phone>
      <email>christine.martinez@wustl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Todd Margolis, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.siteman.wustl.edu</url>
    <description>Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>December 10, 2019</study_first_submitted>
  <study_first_submitted_qc>December 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 18, 2019</study_first_posted>
  <last_update_submitted>June 29, 2020</last_update_submitted>
  <last_update_submitted_qc>June 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GVHD</keyword>
  <keyword>Graft-Versus-Host Disease</keyword>
  <keyword>Ocular Surface</keyword>
  <keyword>Ocular Surface Microbiome</keyword>
  <keyword>Vigamox</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

